How to Help Your Patients Find Felbamate in Stock: A Provider's Guide

If you manage patients with treatment-resistant epilepsy, you've likely fielded the call: a patient or caregiver can't find felbamate at their pharmacy. They've called three locations and come up empty. They're getting close to running out, and they're frightened. These calls are both clinically urgent and operationally disruptive. This guide provides practical, evidence-informed steps your practice can take to help patients maintain consistent felbamate access—and to reduce the volume of crisis calls to your office.

Why Felbamate Access Is an Ongoing Challenge for Your Patients

Felbamate is not in an active FDA shortage. The challenge is structural: because so few patients take it, most retail pharmacies have no standing inventory. The drug exists in wholesale distribution, but pharmacies need to place special orders to obtain it. For your patients—many of whom are already managing significant medical complexity—the time and energy required to track down a monthly prescription is a real burden.

The risk of supply disruption is not trivial. Abrupt discontinuation of felbamate can precipitate rebound seizures, including status epilepticus. Proactive access planning is, in a real sense, part of the clinical management of these patients.

Strategy 1: Establish a Preferred Pharmacy Relationship at Initiation

When you initiate felbamate for a patient, take 5 minutes to establish where they will fill the prescription. Don't leave this to chance. Consider the following approach:

If your clinic has an affiliated outpatient or health-system pharmacy, route the first prescription there. These pharmacies are most familiar with felbamate's documentation requirements and most likely to have it in stock.

If the patient prefers a retail pharmacy, call ahead to confirm they have (or can order) the required dose form and strength before writing the prescription.

For patients in rural or underserved areas, establish a mail-order specialty pharmacy relationship at initiation. Arrange a 90-day supply cadence wherever insurance permits.

Strategy 2: Educate Patients on Proactive Refill Management

Many access crises are avoidable with better patient education. At each visit, reinforce these points:

Start the refill process 10–14 days before running out. Felbamate may require a special pharmacy order with a 24–72 hour lead time. A last-minute refill request risks dangerous supply gaps.

Maintain a list of two or three pharmacies known to stock or order felbamate reliably. Having a backup location reduces time wasted on initial failures.

Never stop taking felbamate without calling your neurologist first. Reinforce this at every visit. Consider including it in your patient discharge instructions as a standing reminder.

Strategy 3: Use medfinder to Offload Pharmacy Search Tasks

When patients can't locate felbamate, the calls often route back to your office staff—who then spend time calling pharmacies themselves. medfinder eliminates this burden. Patients enter their medication, strength, and zip code; medfinder contacts pharmacies to check current stock and texts results to the patient directly.

Consider creating a simple patient handout for your felbamate patients that includes the medfinder website alongside your refill instructions. This one step can significantly reduce the number of access-related calls to your practice.

Strategy 4: Manage Prior Authorization Proactively

Felbamate commonly requires prior authorization (PA) due to its restricted use criteria. PA approvals often have expiration dates, typically 6–12 months. Letting a PA expire is a common—and avoidable—source of supply disruption.

Best practices for PA management:

Track PA expiration dates in your EMR or practice management system and trigger renewal 60 days in advance

Document clinical rationale clearly in the PA request: diagnosis, history of prior AED failures, seizure frequency, and evidence of monitoring compliance

If a PA is denied, file an appeal or request a peer-to-peer review. The patient's epilepsy severity and exhaustion of alternatives should support the case.

Strategy 5: Know When to Revisit the Treatment Plan

If a patient experiences repeated dangerous supply gaps despite all of the above strategies, it may be time to revisit whether felbamate remains the best option for them. The epilepsy treatment landscape has evolved since many of these patients were placed on felbamate. Newer options—particularly cenobamate (Xcopri) for refractory focal seizures—have demonstrated strong efficacy in drug-resistant cases without the same hematologic and hepatic risks.

This is not a decision to take lightly—felbamate often represents years of prior treatment failure, and patients on it may be achieving seizure control that couldn't be achieved with anything else. But chronic supply disruptions are themselves a clinical risk, and that risk must factor into your ongoing benefit-risk assessment.

Documentation and Informed Consent: A Compliance Reminder

The Patient/Physician Acknowledgment Form is a regulatory requirement for felbamate, not optional documentation. It must be obtained before the first prescription and retained in the patient's chart. Some dispensing pharmacies may ask to see proof of this consent, particularly at new fill locations. Ensure your records are complete and that copies are available to the patient to bring to a new pharmacy if needed.

For guidance on helping patients manage cost as well as access, see our article on how to save money on felbamate in 2026, which includes information on coupon programs and patient assistance.